Open Innovation Startups Selected
Joint Research and Commercialization Support Planned
Infrastructure Support Including Overseas Networking

On June 10, the Seoul Metropolitan Government announced that it will collaborate with Celltrion and Daewon Pharmaceutical to nurture promising bio startups in Seoul. The city plans to conduct joint research with the bio startups that were finally selected for this year's open innovation program and will provide support through to commercialization.


A total of four bio startups have been chosen to collaborate with Celltrion. "AinB," which has an artificial intelligence (AI)-based protein antibody development platform, and "Enbiocell," which is developing a technology to formulate GLP-1 derivatives—regarded as next-generation treatments for obesity and diabetes—into oral pills, were selected. "ImitaScience," another selected company, possesses biomimetic multi-organ chip technology that can replace animal testing. "Podotherapeutics" has established a precision medical platform that verifies individual drug responses using patient-derived organoids (mini organs).

On the 10th, attendees are taking a commemorative photo at the 'Seoul Bio Hub-Celtrion Open Innovation Selected Companies Agreement Ceremony' held at the Celtrion Global Biotechnology Research Center in Songdo, Incheon. Seoul City

On the 10th, attendees are taking a commemorative photo at the 'Seoul Bio Hub-Celtrion Open Innovation Selected Companies Agreement Ceremony' held at the Celtrion Global Biotechnology Research Center in Songdo, Incheon. Seoul City

View original image

In the case of Daewon Pharmaceutical, it will work with "Omniamed," which has a technology that selectively activates drugs only in inflamed and cancerous tissues, and "Curiosa Bioscience," which has developed technology to control drug release at the molecular level.


Celltrion and Daewon Pharmaceutical will consider technology validation and joint research and development with these bio startups. They will also help the startups further refine their development and commercialization strategies. The city will provide support such as research and office space and laboratory equipment by utilizing "Seoul Bio Hub" near Hongneung in Dongdaemun-gu. In addition, public infrastructure support, such as overseas networking, will be linked to help promising startups establish themselves in the market.



Lee Sooyeon, Director-General for Economy at the Seoul Metropolitan Government, stated, "For startups, this will be an opportunity to inherit the experience and network of global anchor companies, and for large corporations, it will be a platform to secure innovative technologies for mutual growth. We will spare no effort to support the selected promising startups so that they can grow into unicorn companies leading the global bio market, beyond South Korea."


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing